Substance Use Disorder Program

About Kuleon Bioscience

Kuleon Bioscience is a private, pre-clinical stage biotech founded in 2021 and headquartered in Seattle, Washington, with a focus on neuropsychiatric therapeutics. The company combines deep expertise in small molecule design with an AI-powered drug discovery engine to rapidly identify and patent novel compounds targeting the serotonergic system. Its pipeline is led by programs for substance use disorders (alcohol and drug abuse) currently in IND-enabling studies, supported by a broad intellectual property estate covering millions of novel molecules. Kuleon operates with a hybrid business model, pursuing both in-house development and out-licensing opportunities for its discovered assets.

Therapeutic Areas